Trial Profile

A Randomized, Double-Blind, Single-Center, Phase 2, Efficacy and Safety Study of Autologous HB-adMSCs vs Placebo for the Treatment of Patients With Multiple Sclerosis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Autologous adipose derived mesenchymal stem cells Hope Biosciences (Primary)
Indications Multiple sclerosis
Focus Therapeutic Use
Acronyms HBMS01
Sponsors Hope Biosciences

Most Recent Events

27 Aug 2025 Results published in the Media Release
27 Aug 2025 Primary endpoint has been met. (To investigate the efficacy of intravenous infusions of HB-adMSCs vs placebo in patients with Multiple Sclerosis as determined by improvements in the Multiple Sclerosis Quality of Life (MSQOL) 54 Instrument.)
20 Jun 2024 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com